BCL2 and prostate carcinoma: In prostate cancer, several studies demonstrate that overexpression of antiapoptotic BCL2 proteins are adverse prognostic factors associated with disease progression and therapy resistance.7, 8, 9 Increased expression of these antiapoptotic proteins can suppress apoptosis by sequestering the proapoptosis players and preventing activation BAX and BAK.